Inhibition of the replication of hepatitis B virus in Vitro by oxymatrine

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1411-1419

  Lin, M ^a   Yang, L Y ^a   Li, W Y ^a   Peng, Y P ^a   Zheng, J K ^a  

^a Chaozhou Central Hospital Affiliated to Southern Medical University   (China)

Author keywords

Hepatitis B virus; Oxymatrine; Virus replication

Indexed keywords

ALKALOID; ALPHA2B INTERFERON; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MESSENGER RNA; OXYMATRINE; QUINOLIZINE DERIVATIVE; VIRUS DNA;

APOPTOSIS; ARTICLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NICK END LABELING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; VIROLOGY; VIRUS REPLICATION; WESTERN BLOTTING;

ALKALOIDS; ANTIVIRAL AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IN SITU NICK-END LABELING; INTERFERON ALFA-2B; LIVER NEOPLASMS; QUINOLIZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 77649222193     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323000903700515     Document Type: Article

References (26)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
2. Liu CJ, Chen BF, Chen PJ, et al: Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006; 194: 594-599.
3. Chisari FV, Filippi P, Buras J, et al: Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-6913.
4. Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
5. Sells MA, Zelent AZ, Shvartsman M, et al: Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 1988; 62: 2836-2844.
6. Korba BE, Milman GA: A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 1991; 15: 217-228.
7. Korba BE, Gerin JL: Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 1992; 19: 55-70.
8. Lee JM, Kim HJ, Park JY, et al: Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009; 14: 705-712.
9. Leung N: Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17: 409-414.
10. Liu J, Zhu M, Shi R, et al: Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. Am J Chin Med 2003; 31: 337-354.
11. Long Y, Lin XT, Zeng KL, Zhang L: Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004; 3: 69-72.
12. Lee SJ, Lee HK, Jung MK, et al: In vitro antiviral activity of 1,2,3,4,6-penta-O-galloyl-β-D-glucose against hepatitis B virus. Biol Pharm Bull 2006; 29: 2131-2134.
13. Li CQ, Zhu YT, Zhang FX, et al: Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol 2005; 11: 426-428.
14. Klintschar M, Neuhuber F: Evaluation of an alkaline lysis method for the extraction of DNA from whole blood and forensic stains for STR analysis. J Forensic Sci 2000; 45: 669-673.
15. Cheng G, He YS, Zhou XY: Fluorescence quantitative PCR and its application in detection of hepatitis B virus. Zhonghua Jianyan Yixue Zazhi 1999; 22: 135-136.
16. Delaney WE IV, Miller TG, Isom HC: Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999; 43: 2017-2026.
17. Abdelhamed AM, Kelley CM, Miller TG, et al: Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob Agents Chemother 2003; 47: 324-336.
18. Yamazaki M: The pharmacological studies on matrine and oxymatrine. Yakugaku Zasshi 2000; 120: 1025-1033 [in Japanese].
19. Ding PL, Liao ZX, Huang H, et al: (+)-12α-Hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens. Bioorg Med Chem Lett 2006; 16: 1231-1235.
20. Lu LG, Zeng MD, Mao YM, et al: Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice. World J Gastroenterol 2004; 10: 1176-1179.
21. Li JQ, Chen YX, Zeng MD, et al: The inhibitory effect of oxymatrine on hepatitis B virus in vitro. Chin J Dig 2001; 21: 550-552 [in Chinese].
22. Cheng Y, Ping J, Xu HD, et al: The inhibitory effect of oxymatrine-baicailin compound on hepatitis B viral antigen s secretion in HepG2.2.2.15 cells. Chin Pharm Bull 2006; 10: 1258-1263 [in Chinese].
23. Xu WS, Wang GJ, Miao XH, et al: Effects of oxymatrine on expression of HBV DNA in HepG2.2.15 cells. Acad J Second Mil Med Univ 2002; 23: 72-73 [in Chinese].
24. Chen YF, Tian SJ, Song JZ, et al: Study on pharmacokinetics of Sophora flavescens injection in rabbits. Chin Pharm J 1994; 7: 524-526 [in Chinese].
25. Fei YQ, An FR, Sun L, et al: Pharmacokinetics of matrine injection in healthy volunteers. Chin Hosp Pharm J 2003; 23: 21-22 [in Chinese].
26. Wu XL, Hang TJ, Shen JP, et al: Pharmacokinetics of oxymatrine and its metabolite matrine in healthy volunteers after oral administration of oxymatrine capsule. Chin J Clin Pharm 2007; 23: 37-40 [in Chinese].